Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- ...
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab ...
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results